

**CSE: CDN** 

OTCPINK: AXVEF Frankfurt: A117RU

## CDN MAVERICK REPORTS ON SUCCESSFUL INVESTMENT IN NORAM: NORAM RECEIVES ASSAY RESULTS FOR CVZ-61 WITH HIGH OF 1860PPM: 260FT (79M) OF 1130PPM FROM 107FT (32M) TO 367FT (112M)

Vancouver, British Columbia – December 15, 2020 – CDN Maverick Capital Corp. ("Maverick" or the "Company") (CSE: CDN; OTCPINK:AXVEF; Frankfurt: A117RU) is updating shareholders on its interest in Noram Ventures Inc. ("Noram") (TSX - Venture: NRM / Frankfurt: N7R / OTCQB: NRVTF) who are pleased to announce that the Company has received the assay results for drill hole CVZ-61 (shown below). Approximately 298ft (91m) of lithium claystone was intersected, of which, 260 ft (79m) ran an average of 1130ppm. This average is consistent with Noram's current resource estimate of 124 million tonnes at 1136 ppm lithium as Indicated Resources, and 77 million tonnes lithium at 1045 ppm lithium as Inferred Resources (900 ppm Li cut-off: 1.18 million tonnes lithium carbonate equivalent – "LCE") after the completion of the prior 4 phases of drilling.

"The completion of thick high-grade lithium claystone intersections such as CVZ-61 confirm our belief that the resource extends to the south beyond the currently defined resource area. These results will add substantially to the resource estimate and we anticipate the results for CVZ-62 and CVZ-63 to do the same" commented Brad Peek, consulting geologist and Qualified Person for this and all 4 of the previous drilling phases of Noram's Zeus lithium property.




Figure 1. Zeus Property map showing a) location of current Indicated and Inferred resources at >900ppm Li cut-off; b) location of drill sites completed or in progress (seen in green) to date for the Phase V 2020 program. Proposed drill sites not yet explored indicated in white.

The summary of assay results is as follows:

Hole ID	Sample No.	From (ft)	To (ft)	Depth to Top (m)	Depth to Base (m)	Recvd Wt. (Kg)	Li (ppm)
CVZ-61	1710101	17	27	5.2	8.2	2.22	540
CVZ-61	1710102	27	37	8.2	11.3	2.32	570
CVZ-61	1710103	37	47	11.3	14.3	2.48	640
CVZ-61	1710104	47	57	14.3	17.4	2.89	730
CVZ-61	1710105	57	67	17.4	20.4	2.89	870
CVZ-61	1710106	67	77	20.4	23.5	0.18	680
CVZ-61	1710107	77	87	23.5	26.5	2.41	680
CVZ-61	1710108	87	97	26.5	29.6	2.74	620
CVZ-61	No Sample	97	107	29.6	32.6		
CVZ-61	1710109	107	117	32.6	35.7	1.59	970
CVZ-61	1710110	117	127	35.7	38.7	2.5	900
CVZ-61	1710111	127	137	38.7	41.8	1.18	790
CVZ-61	1710112	137	147	41.8	44.8	3.11	920
CVZ-61	1710113	147	157	44.8	47.9	2.83	1860
CVZ-61	1710114	157	167	47.9	50.9	2.63	1140
CVZ-61	1710115	167	177	50.9	53.9	2.37	920
CVZ-61	1710116	177	187	53.9	57.0	2.88	1230
CVZ-61	1710117	187	197	57.0	60.0	0.89	820
CVZ-61	1710118	197	207	60.0	63.1	2.79	1180
						_	
CVZ-61	1710120	207	217	63.1	66.1	3.42	1480
CVZ-61	1710121	217	227	66.1	69.2	1.24	1650
CVZ-61	1710122	227	237	69.2	72.2	3.41	1360
CVZ-61	1710123	237	247	72.2	75.3	3.05	1440
CVZ-61	1710124	247	257	75.3	78.3	3.69	1260
CVZ-61	1710125	257	267	78.3	81.4	1.73	1120
CVZ-61	1710126	267	277	81.4	84.4	2.87	1240
CVZ-61	1710127	277	287	84.4	87.5	2.18	970
CVZ-61	1710128	287	297	87.5	90.5	3.36	1060
CVZ-61	1710129	297	307	90.5	93.6	1.59	930
CVZ-61	1710130	307	317	93.6	96.6	3.32	990
CVZ-61	1710131	317	327	96.6	99.7	3.16	940
CVZ-61	1710132	327	337	99.7	102.7	2.12	1180
CVZ-61	1710133	337	347	102.7	105.8	1.87	940
CVZ-61	1710134	347	357	105.8	108.8	2.91	1150
CVZ-61	1710135	357	367	108.8	111.9	2.8	940
CVZ-61	1710136	367	377	111.9	114.9	2.32	860
CVZ-61	1710137	377	387	114.9	118.0	3.05	750
CVZ-61	1710138	387	397	118.0	121.0	3.31	720
CVZ-61	1710139	397	407	121.0	124.1	3.05	760
CVZ-61	1710140	407	417	124.1	127.1	3.01	760

The samples were analyzed by ALS Global Laboratories, Vancouver, B.C. using the ME-MS61 method, which includes a four-acid digestion. The samples were accompanied by 4 QA/QC sample standards, all of which returned results within their respective normal ranges.

The technical information contained in this news release has been reviewed and approved by Brad Peek., M.Sc., CPG, who is a Qualified Person with respect to Noram's Clayton Valley Lithium Project as defined under National Instrument 43-101.

## About CDN Maverick Capital Corp.

CDN Maverick Capital Corp. is a Vancouver-based junior resource company with projects in North America. CDN Maverick is focused on the development of the following mineral properties:

The Ranger Lake Gold Project consists of 1,107 hectares of prospective gold exploration in southern Quebec, Canada.

The Rainbow Canyon Gold Property consists of 417 hectares of prospective gold exploration in the Olinghouse mining district, in the Washoe County Nevada.

## ON BEHALF OF THE BOARD OF DIRECTORS

"Sandy MacDougall" Chairman & Director Phone: (604) 662-7902

This news release contains projections and forward - looking information that involve various risks and uncertainties regarding future events. Such forward - looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company. The following are important factors that could cause the Company's actual results to differ materially from those expressed or implied by such forward looking statements; the uncertainty of future profitability; and the uncertainty of access to additional capital. These risks and uncertainties could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and expressed qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking information should circumstance or management's estimates or opinions change.

Neither the Canadian Securities Exchange ("CSE") nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.